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Introduction: Cerebrospinal fluid (CSF) total α-synuclein is considered a potential biomarker 
for Parkinson’s disease (PD), but little is known about the evolution of this marker during the 
course of the disease. Our objective was to investigate whether CSF total α-synuclein 
concentrations change over time and are associated with motor and cognitive function in PD.  
Methods: CSF total α-synuclein concentrations were quantified in 56 longitudinally followed 
PD patients, 27 of whom provided CSF repeatedly 2 and/or 4 years later. Another 18 subjects 
were included as controls. The samples were analyzed using two independent, validated ELISA 
methods: our recently developed and validated in-house ELISA and a commercial kit from 
BioLegend. 
Results: CSF total α-synuclein levels did not distinguish PD patients from controls, displayed 
no substantial changes during a period of up to 4 years, and did not predict subsequent motor 
or cognitive decline. These findings were consistent for both analytical methods. 
Conclusion: Our findings do not support the clinical utility of total α-synuclein as a single 
diagnostic or prognostic biomarker in PD. 




Parkinson’s disease (PD) is characterized by a remarkable clinical heterogeneity, with 
substantial variation in disease progression and considerable overlap with other 
neurodegenerative diseases. Therefore, reliable biomarkers for diagnosis and prognosis of PD 
are urgently needed. Given the central role of α-synuclein aggregation in PD pathogenesis, and 
because α-synuclein levels are a major determinant of its neurotoxicity [1], it is of great interest 
to investigate the potential of α-synuclein as a diagnostic and prognostic biomarker. In this 
respect, cerebrospinal fluid (CSF) is considered the most promising source. Most, but not all 
previous studies report a trend towards lower total CSF α-synuclein levels in PD compared to 
controls, though with substantial overlap between diagnostic groups [2]. Only a few studies 
have reported longitudinal measurements of α-synuclein, also with conflicting results [3-6]. 
Hence, there is a need for additional longitudinal studies to track CSF α-synuclein changes 
during the disease course. We also examined whether total α-synuclein concentrations were 
associated with motor symptoms and neuropsychological performance, and their changes over 
a period of up to 4 years. In addition, we compared total α-synuclein levels of PD patients with 
those of the controls. 
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Materials and methods 
Patients 
All PD patients were enrolled in the Norwegian ParkWest study, an ongoing, prospective, 
population-based, longitudinal cohort study of PD in Southwestern Norway [7]. Participants 
included a subset of 56 PD patients (median disease duration 4.8 years), of whom 27 also 
provided CSF at one or two follow-up visits 2 and 4 years later (Figure 1 and Table 1). The 
patients were followed prospectively by movement disorders neurologists and fulfilled the 
National Institute of Neurological Disorders and Stroke [8] and UK Brain Bank [9] diagnostic 
criteria of PD from study entry to latest visit. Exclusion criteria were secondary parkinsonism 
and dementia during the first year of motor onset to eliminate patients with dementia with Lewy 
bodies and other dementias, including Alzheimer’s disease. All patients underwent a uniform 
and standardized examination program at each visit. Disease severity was determined using the 
Unified Parkinson’s Disease Rating Scale (UPDRS) [10] part II and III, and disease stage was 
evaluated using the Hoehn and Yahr scale (H&Y) [11]. Cognitive assessments included the 
Mini-Mental State Examination (MMSE) [12] as a measure of global cognition, and a 
neuropsychological test battery assessing the following domains: verbal memory (California 
Verbal Learning Test II [CVLT-II] [13], which included total immediate recall [sum of trials 
1–5], short-delay, and long-delay free recall scores), attention (Stroop word reading and color 
naming) [14], executive functioning (Semantic Verbal Fluency Test [15], and Stroop 
interference condition) and visuospatial skills (Visual Object and Space Perception battery 
[VOSP] Silhouettes and Cube subtests) [16]. Severity of depressive symptoms was determined 
using the Montgomery and Aasberg Depression Rating Scale (MADRS) [17]. 
Controls 
The control group consisted of 18 subjects without known brain disease, who underwent 
elective neurological examination or orthopedic surgery at Stavanger University Hospital. 
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CSF sample treatment 
CSF collection and sample treatment was conducted according to standardized procedures, as 
described elsewhere [18]. The CSF samples were centrifuged at 2000g for 10 minutes and 
frozen in polypropylene tubes at -80°C. The samples were subjected to one freeze-thaw event 
for aliquotation purposes.  
-synuclein measurement 
The in-house assay procedures and characteristics have been described in detail previously [19]. 
In brief, the ELISA assay fulfills the newest validation criteria [20], has a lower limit of 
quantification of 36.3pg/mL and requires less than 15µL CSF. The samples were analyzed in 
duplicates at the Neuroscience Research Laboratory at Stavanger University Hospital, Norway, 
with plate-to-plate variation below 6%. An identical set of CSF aliquots were sent to the Clinical 
Neurochemistry Laboratory at Sahlgrenska University Hospital, Sweden for analysis with the 
commercial ELISA kit from BioLegend (#844101; BioLegend, San Diego, USA), with plate-
to-plate variation below 5%. There was a high correlation between the two assays (ρ=0.785, 
P<0.001), which were independent in terms of site, date of analysis and personnel. 
Hemoglobin measurement  
To assess possible blood contamination as source of α-synuclein, the samples were analyzed 
for hemoglobin content using a commercial kit (#E88-135, Bethyl Laboratories, Montgomery, 
USA). Samples with hemoglobin concentrations above 200µg/mL were excluded from the 
study. 
Statistical analysis 
Standard curve fitting (4-parameter logistic fit), plotting of calibrator curves and calculation of 
total α-synuclein concentrations were performed using the Meso Scale Discovery Workbench 
4.0 software (Meso Scale Discovery, Gaithersburg, USA). Descriptive statistics for continuous 
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variables are presented as means for symmetrically distributed data, as geometric means for 
right skewed, small samples, or otherwise as medians, and with full ranges. Categorical 
variables are presented with counts and percentages. Between-group comparisons were 
performed by Mann-Whitney U for continuous variables. Within-patient comparisons were 
performed by paired samples t-tests for symmetrically distributed differences, or Wilcoxon 
paired signed rank tests for non-normally distributed data. Possible relationships between CSF 
total α-synuclein and clinical and neuropsychological performance at CSF sampling were 
assessed by linear regression analysis with adjustment for age and sex. To assess associations 
between CSF total α-synuclein and clinical and neuropsychological measures within 4 years 
after CSF sampling, we used linear random intercept models with adjustment for age and sex, 
and with time and CSF total α-synuclein included as main effects and with an interaction term, 
that measures the possible differential effect of levels of α-synuclein on progression slopes. 
Spearman’s rank correlation was used to assess strength of association between the two 
analytical methods. All analyses were conducted using SPSS 23 (IBM, Armonk, USA).  Two-
tailed P-values <0.05 were considered statistically significant. For multiple comparisons, 
Bonferroni correction was applied with two-tailed P-values <0.0036 (14 tests) considered 
significant. 
Research Ethics 
All procedures were approved by The Norwegian Regional Committee for Medical and Health 
Research Ethics, and signed written informed consent was obtained from all participants.




There was no significant difference in CSF total α-synuclein concentrations between PD 
patients (N=56, 55% males, median age 69.6) and controls (N=18, 50% males, median age 
67.7), as measured by the in-house assay (469 [178-1333] pg/ml vs. 424 [175-852] pg/ml; 
P=0.392), and the BioLegend kit (677 [259-1723] pg/ml vs. 747 [306-1623] pg/ml; P=0.366) 
(Figure 2A and B). In the PD patients, CSF levels were not significantly associated with clinical 
or cognitive performance cross-sectionally (Table s1), nor did they predict the rate of motor or 
cognitive decline longitudinally during up to 4 years of follow-up (Table s2), after correction 
for multiple testing. A separate analysis excluding patients with PD dementia or depression did 
not alter the overall result (data not shown). Finally, we found no consistent pattern nor any 
statistically significant changes in CSF total α-synuclein concentrations during 4 years of 
follow-up (N=27, all P>0.1; Table 1, Figure 2A and B), although some variation over time was 
observed in a few individuals (Figure 2C and D).  
 




In this study of PD patients recruited from a prospective, population-based longitudinal study, 
we found that total CSF α-synuclein levels, measured by two independent analytical methods, 
1) did not differ from controls, adding to the list of studies reporting comparable levels between 
PD and controls [2]; 2) displayed no significant changes during a period of up to 4 years, and 
3) did not predict the rate of motor, cognitive or neuropsychological decline, in agreement with 
previous studies [2]. Overall, these findings do not support the clinical utility of total α-
synuclein as a single diagnostic or prognostic biomarker in PD. 
In recent years, CSF total α-synuclein and other α-synuclein species have emerged as potential 
diagnostic and prognostic biomarkers in PD [2]. However, while numerous cross-sectional 
studies have investigated the diagnostic value of total α-synuclein, very few longitudinal studies 
have been conducted to explore changes of CSF total α-synuclein over time, and with 
inconsistent findings. Two studies utilizing data from the DATATOP cohort found either 
decreasing [3] or increasing [4] α-synuclein levels over a 2-year period. These apparently 
contradicting findings might be explained by differences in pre-analytical factors or detection 
methods [4]. Another study, using the Swedish BioFINDER cohort, found a minor increase at 
the group level in CSF α-synuclein levels over a period of 2 years in PD patients with long (>5 
years) but not shorter (≤5 years) disease duration [5]. Finally, a recent report from the PPMI 
study revealed no change over a period of ½ and 1 year in early PD [6], in line with results from 
our 4-year longitudinal study.  
In Alzheimer’s disease, it is well established that the deposition of amyloid-beta into 
extracellular plaques translates into decreased CSF concentrations of this protein [21]. In PD 
however, α-synuclein aggregates into Lewy bodies intracellularly, making it less clear how 
these pathological events, and their spread in the brain, influence the dynamics of α-synuclein 
in CSF. Different hypotheses explaining CSF changes of total α-synuclein levels in either 
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direction have been proposed. A reduction over time could be explained by the sequestration 
and aggregation of α-synuclein in soluble fibrils and Lewy bodies [2], while an increase in 
levels could result from progressive neuronal damage [22], possibly due to release of α-
synuclein from degenerating cells. Indeed, some PD studies have shown strong correlations 
between CSF levels of α-synuclein and tau, an acknowledged marker of neuronal degeneration 
[23, 24]. Furthermore, a marked increase in levels of α-synuclein has been found in disorders 
with widespread and progressive neurodegeneration, such as Creutzfeldt-Jakob disease and AD 
[25-29]. A co-occurrence of such contrary events may result in no overall change in total α-
synuclein levels, as found in our study. Furthermore, Hall et al. [5] hypothesized that the 
evolution of α-synuclein levels in PD might be bimodal with levels decreasing in early disease 
due to intracellular accumulation, followed by an increase with clinical disease progression 
reflecting progressive neuronal damage. In our study, CSF was obtained from patients at least 
3 years after motor onset, and applying the bimodal hypothesis, patients may already have 
reached a plateau in the second stage of the disease development. This might explain why there 
was no further increase in α-synuclein levels with continued disease progression. However, 
more longitudinal studies with multiple sampling covering longer periods are needed to fully 
clarify this issue.   
Another implication of the bimodal hypothesis is that the potential diagnostic value of α-
synuclein may be offset by individual differences in the neuropathological effects accountable 
for changes in total α-synuclein levels in CSF. Therefore, an approach with α-synuclein as part 
of a biomarker panel, including other species of α-synuclein, such as oligomeric- and 
phosphorylated α-synuclein, could be a promising alternative [30]. 
A limitation of this study is the relatively small sample size, particularly of those with repeated 
CSF measurements, contributing to wide confidence intervals. In addition, the limited sample 
size did not allow for subgroup analysis (e.g. after stratification into different endophenotypes). 
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Therefore, we cannot exclude the possibility of associations of CSF α-synuclein with clinical 
features in certain PD subgroups. Another limitation, shared by similar studies, is that patients 
with milder symptoms are possibly more likely to consent to repetitive lumbar puncture, which 
could result in a potential selection bias. Finally, the lack of other CSF markers than α-synuclein 
(e.g. tau) and the inhomogeneous time intervals between lumbar punctures in those with 
repeated measures can be considered further limitations of this study. Strengths include the 
unselected PD cohort, comprehensive, prospective clinical and neuropsychological 
assessments, and study design with repeated CSF samples over a longer time interval than in 
previous studies. Finally, we followed well-established and standardized routines for collection 
and handling of CSF samples, and applied two independent, validated methods to quantify total 
α-synuclein levels with consistent findings. 
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